Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | BLM | P54132 | 2/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | SCN1A | P35498 | 1/20 | 0.39 |
| ▸ | SCN4A | P35499 | 1/20 | 0.39 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14535334 | 1.00 | KMT2A (0.42) | KMT2AMEN1CYP1A2POLBTSHR | |
| SCHEMBL26111035 | 0.80 | DRD2 (0.43) | KMT2AMEN1MMP2MMP9 | |
| SCHEMBL26113825 | 0.80 | CYP19A1 (0.43) | ALDH1A1PMP22 | |
| SCHEMBL26116295 | 0.77 | SMN1; SMN2 (0.35) | KMT2AMEN1POLBALDH1A1MAPT | |
| SCHEMBL18822335 | 0.76 | GRIN1 (0.48) | KMT2AMEN1CYP1A2POLBTSHR | |
| SCHEMBL26499732 | 0.76 | ABAT (0.36) | MAPT | |
| SCHEMBL22438572 | 0.73 | BACE1 (0.41) | KMT2AMEN1CYP1A2POLBTSHR | |
| SCHEMBL29153345 | 0.73 | MEN1 (0.38) | KMT2AMEN1CYP1A2POLBTSHR | |
| SCHEMBL8942143 | 0.71 | KMT2A (0.42) | KMT2AMEN1CYP1A2POLBTSHR | |
| SCHEMBL2399034 | 0.68 | MAPT (0.43) | KMT2AMEN1MAPTKCNH2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070112199-A1 | Asymmetric aldol additions using bifunctional cinchona-alkaloid-based catalysts | BRANDEIS UNIVERSITY (US) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112199-A1 | Asymmetric aldol additions using bifunctional cinchona-alkaloid-based catalysts | AKR1C2, AKR1A1, AKR1B1 | KMT2A 622/4885MEN1 877/4885CYP1A2 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.